Manufacturers improved purification techniques, introduced standardized strengths and developed new long-acting insulins. Although not identical to human insulin, animal based insulins were a highly ...

Use of the long-acting insulin analogs glargine and detemir does not reduce the risk of diabetic ketoacidosis in children and adolescents with type 1 diabetes mellitus (T1DM), compared with the ...

For information about short-acting insulin and other types of insulin ... Having a high level of blood sugar over a long period of time can cause serious problems, including kidney disease ...

One wrong move — a little too much insulin or a forgotten dose ... This could improve both the short-term and long-term risks ...

“Rescinding the cap on insulin at $35 only makes pharmaceutical richer and everyday Americans, including MAGA voters, ...

To mimic physiological insulin release, both long-acting and short-acting insulin preparations are needed. After decades of optimizations to develop longer-acting insulin preparations to reduce ...

The FDA approved its short-acting insulin, Fiasp (insulin aspart injection) in September, and its long-acting insulin Tresiba (insulin degludec) got US approval late last year. [caption id ...

Trials including commercially available formulations of insulin detemir or insulin glargine were compared with NPH. Pertinent English-language clinical trials published between 2000 and 2006 were ...

Diabetes is a number of diseases that involve problems with the hormone insulin. There is no cure for diabetes. The warning signs of diabetes can be so mild that you don't notice them. That's ...

Key market drivers of the Insulin Pen and Pump market include the rising prevalence of diabetes, advancements in insulin delivery technologies ...